2. Academic Validation
  3. IL-17C in human mucosal immunity: More than just a middle child

IL-17C in human mucosal immunity: More than just a middle child

  • Cytokine. 2021 Oct;146:155641. doi: 10.1016/j.cyto.2021.155641.
Stephanie Swedik 1,  Abson Madola 2,  Alan Levine 3
Affiliations

Affiliations

  • 1 Department of Molecular Biology and Microbiology, Case Western Reserve University, 10900 Euclid Ave, Cleveland, OH 44106, United States.
  • 2 Department of Biology, Case Western Reserve University, 10900 Euclid Ave, Cleveland, OH 44106, United States.
  • 3 Department of Molecular Biology and Microbiology, Case Western Reserve University, 10900 Euclid Ave, Cleveland, OH 44106, United States; Departments of Pathology, Pharmacology, Medicine, and Pediatrics, Case Western Reserve University, 10900 Euclid Ave, Cleveland, OH 44106, United States. Electronic address: alan.levine@case.edu.
PMID: 34293699 DOI: 10.1016/j.cyto.2021.155641
Abstract

Interleukin-17C (IL-17C) is an understudied member of the IL-17 family of cytokines. Its synthesis is induced by both cytokines and pathogenic stimuli in a variety of cell types, most often expressed at mucosal and barrier surfaces. IL-17C expression is dysregulated in a variety of autoinflammatory and autoimmune diseases including inflammatory bowel disease, psoriasis, and atopic dermatitis, yet it is protective against Bacterial infections of the gut, skin, and lungs. In this review we highlight studies on IL-17C regulation and its function at human mucosal surfaces. Understanding the relationship between IL-17C and autoinflammatory and autoimmune diseases of the mucosa and defining the beneficial and pathogenic functions of the cytokine in inflammatory responses are the first steps in determining the potential for IL-17C as a therapeutic target.

Keywords

Barrier surface; Chronic obstructive pulmonary disease; H. pylori; IL-17C; Inflammatory bowel disease; Psoriasis.

Figures
Products